Kus, T.Cicin, I.2024-05-192024-05-1920241750-743Xhttps://doi.org/10.2217/imt-2023-0184https://hdl.handle.net/20.500.12713/4330A consensus guideline, iRECIST, was developed by the Response Evaluation Criteria in Solid Tumours (RECIST) working group for the use of the modified RECIST version 1.1 in cancer immunotherapy trials. iRECIST was designed to separate pseudoprogression from real progression. However, this is not the only ambiguous situation. In clinical immunotherapy trials, stable disease may reflect three tumor responses, including real stable disease, progressive disease and responsive disease. The prediction of a “true complete/partial response” is also important. Much data has accumulated showing that ctDNA can guide decisions at this point; thus, integrating ctDNA into the RECIST 1.1 criteria may help to distinguish a true tumor response type earlier in patients treated with immunotherapy; however, prospectively designed validation studies are needed. © 2024 Expert Publishing Medicine Ltd.eninfo:eu-repo/semantics/closedAccessCtdnaİmmunotherapyİrecıstPhase 2Recıst 1.1Tumor AssesmentReview Article165319329381971422-s2.0-8518465850010.2217/imt-2023-0184Q2